I. To determine the progression‐free survival during the first phase of the study (PFS1) in patients with metastatic colorectal cancer treated with single agent ziv‐aflibercept after progressing on leucovorin calcium, fluorouracil, oxaliplatin (FOLFOX) and leucovorin calcium, fluorouracil, irinotecan hydrochloride (FOLFIRI) with bevacizumab +/‐ cetuximab or panitumumab.